Amended filing updates merger exchange ratio effects
Yarrow Bioscience filed an amended Form 8-K to update its audited financial statements to reflect the effects of the merger exchange ratio disclosed in Note 1.
Baker Tilly’s audit opinion remained unqualified, with the report dated March 31, 2026 and a revised date of Aug. 13, 2026 for the exchange-ratio effects.
The filing also reflects the completed merger on July 27, 2026, when VYNE issued 2,130,731 shares of common stock based on an exchange ratio of 0.7171.
The transaction was accounted for as a reverse recapitalization, with Yarrow treated as the accounting acquirer.
YARW•
